After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.